{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T18:25:30Z","timestamp":1776882330502,"version":"3.51.2"},"reference-count":51,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T00:00:00Z","timestamp":1545350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"funder":[{"name":"National Institutes of Health grants","award":["AI099512"],"award-info":[{"award-number":["AI099512"]}]},{"name":"National Major Science and Technology Special Project","award":["2013ZX10003008-003-001"],"award-info":[{"award-number":["2013ZX10003008-003-001"]}]},{"name":"National Major Science and Technology Special Project","award":["2017ZX10202301-003-001"],"award-info":[{"award-number":["2017ZX10202301-003-001"]}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2018,12,14]]},"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:p>The current treatment for multidrug-resistant tuberculosis (MDR-TB) takes a lengthy period of 18\u201324\u2005months and has a poor cure rate of 50\u201360%. A multicenter, prospective cohort study was conducted to assess the role of testing for molecular susceptibility to pyrazinamide (PZA) in optimising treatment for MDR-TB.<\/jats:p><jats:p>We assigned 76 patients to an optimised molecular susceptibility group and 159 patients to a regular treatment group where PZA susceptibility was not determined. Of these patients, 152 were matched after propensity score matching (76 in the optimised group and 76 in the regular group). Treatment success rate was measured in the propensity-matched cohort as the primary outcome.<\/jats:p><jats:p>Patients in the optimised group achieved a higher treatment success rate than those in the regular group (76.3%<jats:italic>versus<\/jats:italic>55.3%, p=0.006). Of 51 patients with isolates that were susceptible to PZA and who were receiving a 12-month regimen, 42 (82.4%) were treated successfully. The optimised group showed faster culture conversion than the regular group (p=0.024). After exclusion of pre-extensively drug-resistant TB (pre-XDR-TB), the treatment outcome in the optimised group was still better than the regular group (83.1%<jats:italic>versus<\/jats:italic>62.1%, p=0.009).<\/jats:p><jats:p>Introducing molecular susceptibility testing for PZA improved the treatment outcomes for MDR-TB without the use of new drugs. Introducing PZA for patients with PZA-susceptible (PZA-S) MDR-TB allows the current regimen to be shortened to 12\u2005months with comparable success rates to the World Health Organization (WHO) recommended shorter regimen.<\/jats:p>","DOI":"10.1183\/13993003.01770-2018","type":"journal-article","created":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T19:51:28Z","timestamp":1545421888000},"page":"1801770","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort\u00a0study"],"prefix":"10.1183","volume":"53","author":[{"given":"Feng","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenlong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junlian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jichan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiqing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peijun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfeng","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuli","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zumo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heqing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qihui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2018,12,21]]},"reference":[{"key":"2024102100455415000_53.3.1801770.1","unstructured":"Global Tuberculosis Report 2017 . Geneva, World Health Organization, 2017. http:\/\/apps.who.int\/medicinedocs\/documents\/s23360en\/s23360en.pdf"},{"key":"2024102100455415000_53.3.1801770.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02308-2016"},{"key":"2024102100455415000_53.3.1801770.3","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0080-2015"},{"key":"2024102100455415000_53.3.1801770.4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-2600(17)30079-6","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis","volume":"5","author":"Dheda","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024102100455415000_53.3.1801770.5","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-2292-x"},{"key":"2024102100455415000_53.3.1801770.6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1740774516665090","article-title":"A Bayesian response-adaptive trial in tuberculosis: the endTB trial","volume":"14","author":"Cellamare","year":"2016","journal-title":"Clin Trials"},{"key":"2024102100455415000_53.3.1801770.7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1164\/rccm.201606-1097LE","article-title":"Limited benefit of the new shorter multidrug-resistant tuberculosis regimen in Europe","volume":"194","author":"Lange","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102100455415000_53.3.1801770.8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02267-2017"},{"key":"2024102100455415000_53.3.1801770.9","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1164\/rccm.201702-0278OC","article-title":"Impact of point-of-care xpert MTB\/RIF on tuberculosis treatment initiation: a cluster-randomized trial","volume":"196","author":"Lessells","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102100455415000_53.3.1801770.10","doi-asserted-by":"crossref","first-page":"MGM2-0023-2013","DOI":"10.1128\/microbiolspec.MGM2-0023-2013","article-title":"Mechanisms of pyrazinamide action and resistance","volume":"2","author":"Zhang","year":"2014","journal-title":"Microbiol Spectr"},{"key":"2024102100455415000_53.3.1801770.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00223-2017"},{"key":"2024102100455415000_53.3.1801770.12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw376"},{"key":"2024102100455415000_53.3.1801770.13","first-page":"6","article-title":"The curious characteristics of pyrazinamide: a review","volume":"7","author":"Zhang","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102100455415000_53.3.1801770.14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00226-17"},{"key":"2024102100455415000_53.3.1801770.15","doi-asserted-by":"publisher","DOI":"10.1016\/0007-0971(81)90046-2"},{"key":"2024102100455415000_53.3.1801770.16","unstructured":"Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR\/RR-TB). Geneva, World Health Organization, 2018. www.who.int\/tb\/publications\/2018\/WHO_RapidCommunicationMDRTB.pdf"},{"key":"2024102100455415000_53.3.1801770.17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00630-11"},{"key":"2024102100455415000_53.3.1801770.18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133869"},{"key":"2024102100455415000_53.3.1801770.19","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.ijmyco.2016.10.015","article-title":"The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide","volume":"5","author":"Daneau","year":"2016","journal-title":"Int J Mycobacteriology"},{"key":"2024102100455415000_53.3.1801770.20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00498-16"},{"key":"2024102100455415000_53.3.1801770.21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001300"},{"key":"2024102100455415000_53.3.1801770.22","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1038\/emi.2012.18","article-title":"\u201cZS-MDR-TB\u201d versus \u201cZR-MDR-TB\u201d: improving treatment of MDR-TB by identifying pyrazinamide susceptibility","volume":"1","author":"Zhang","year":"2012","journal-title":"Emerg Microbes Infect"},{"key":"2024102100455415000_53.3.1801770.23","doi-asserted-by":"publisher","DOI":"10.1038\/nm0696-662"},{"key":"2024102100455415000_53.3.1801770.24","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05435-11"},{"key":"2024102100455415000_53.3.1801770.25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01550-10"},{"key":"2024102100455415000_53.3.1801770.26","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01819-14"},{"key":"2024102100455415000_53.3.1801770.27","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04541-14"},{"key":"2024102100455415000_53.3.1801770.28","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00073611"},{"key":"2024102100455415000_53.3.1801770.29","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.1208813","article-title":"Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis","volume":"333","author":"Shi","year":"2010","journal-title":"Science"},{"key":"2024102100455415000_53.3.1801770.30","unstructured":"Definitions and reporting framework for tuberculosis-2013 revision . Geneva, World Health Organization, 2013. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/79199\/9789241505345_eng.pdf;jsessionid=A05DE62B4AB06CFABBF6B447D10BEA8B?sequence=1"},{"key":"2024102100455415000_53.3.1801770.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.10.012"},{"key":"2024102100455415000_53.3.1801770.32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12879-017-2230-2","article-title":"Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine","volume":"17","author":"Aibana","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2024102100455415000_53.3.1801770.33","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwt212"},{"key":"2024102100455415000_53.3.1801770.34","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01300-12"},{"key":"2024102100455415000_53.3.1801770.35","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0077OC"},{"key":"2024102100455415000_53.3.1801770.36","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0075"},{"key":"2024102100455415000_53.3.1801770.37","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0535"},{"key":"2024102100455415000_53.3.1801770.38","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(85)90040-6"},{"key":"2024102100455415000_53.3.1801770.39","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"key":"2024102100455415000_53.3.1801770.40","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1056\/NEJMoa1614915","article-title":"Evaluation of a rapid molecular drug-susceptibility test for tuberculosis","volume":"377","author":"Xie","year":"2017","journal-title":"N Engl J Med"},{"key":"2024102100455415000_53.3.1801770.41","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200308-1159OC"},{"key":"2024102100455415000_53.3.1801770.42","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05385-11"},{"key":"2024102100455415000_53.3.1801770.43","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-10-223"},{"key":"2024102100455415000_53.3.1801770.44","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00993-2016"},{"key":"2024102100455415000_53.3.1801770.45","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00147014"},{"key":"2024102100455415000_53.3.1801770.46","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00001913"},{"key":"2024102100455415000_53.3.1801770.47","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01612-2016"},{"key":"2024102100455415000_53.3.1801770.48","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1473-3099(18)30104-X","article-title":"Precision medicine for drug-resistant tuberculosis in high-burden countries: is individualised treatment desirable and feasible?","volume":"18","author":"Cox","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2024102100455415000_53.3.1801770.49","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02678-2017"},{"key":"2024102100455415000_53.3.1801770.50","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01354-2017"},{"key":"2024102100455415000_53.3.1801770.51","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01163-2018"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01770-2018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:33:28Z","timestamp":1740382408000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01770-2018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,21]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,14]]},"published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1183\/13993003.01770-2018"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01770-2018","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,21]]}}}